​

Artiva Biotherapeutics (ARTV) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ARTV Stock Forecast

Artiva Biotherapeutics (ARTV) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $20.50, with a high of $23.00 and a low of $18.00. This represents a 415.08% increase from the last price of $3.98.

ARTV Stock Rating

Artiva Biotherapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

ARTV Price Target Upside V Benchmarks

TypeNameUpside
StockArtiva Biotherapeutics415.08%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.98$3.98$3.98
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Nov, 2524---6
Oct, 2524---6
Sep, 2524---6
Aug, 2524---6
Jul, 2524---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 13, 2024David NierengartenWedbush$18.00$11.2260.43%352.26%
Aug 13, 2024Gil BlumNeedham$23.00$11.22104.99%477.89%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 17, 2025WedbushOutperformOutperformhold
Dec 30, 2024H.C. WainwrightBuyinitialise
Sep 03, 2024Cowen & Co.BuyBuyhold
Aug 13, 2024NeedhamBuyinitialise
Aug 13, 2024WedbushOutperforminitialise
Aug 13, 2024Cowen & Co.Buyinitialise
Aug 13, 2024Cantor FitzgeraldOverweightinitialise
Aug 13, 2024JefferiesBuyinitialise

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast$-4.95$-2.83
High Forecast$-3.63$-2.42
Low Forecast$-6.25$-3.21
Surprise %--

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast$400.00K$75.36M
High Forecast$550.00K$75.36M
Low Forecast$250.00K$75.36M
Surprise %--

Net Income Forecast

$-60M $-52M $-44M $-36M $-28M $-20M Dec 24 Dec 25
Dec 24Dec 25
Reported--
Avg Forecast$-46.31M$-26.47M
High Forecast$-33.96M$-22.64M
Low Forecast$-58.47M$-30.03M
Surprise %--

ARTV Forecast FAQ

Is Artiva Biotherapeutics stock a buy?

Artiva Biotherapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Artiva Biotherapeutics is a favorable investment for most analysts.

What is Artiva Biotherapeutics's price target?

Artiva Biotherapeutics's price target, set by 4 Wall Street analysts, averages $20.5 over the next 12 months. The price target range spans from $18 at the low end to $23 at the high end, suggesting a potential 415.08% change from the previous closing price of $3.98.

How does Artiva Biotherapeutics stock forecast compare to its benchmarks?

Artiva Biotherapeutics's stock forecast shows a 415.08% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Artiva Biotherapeutics over the past three months?

  • November 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Artiva Biotherapeutics’s EPS forecast?

Artiva Biotherapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-4.95, marking a 0% decrease from the reported - in 2023. Estimates for the following years are.

What is Artiva Biotherapeutics’s revenue forecast?

Artiva Biotherapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $400K, reflecting a 0% decrease from the reported - in 2023. The forecast for.

What is Artiva Biotherapeutics’s net income forecast?

Artiva Biotherapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-46.305M, representing a 0% decrease from the reported - in 2023. Projections indicate .